2010
Impact of Bivalirudin Therapy in High-Risk Patients With Acute Myocardial Infarction 1-Year Results From the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) Trial
Parodi G, Antoniucci D, Nikolsky E, Witzenbichler B, Guagliumi G, Peruga JZ, Stuckey T, Dudek D, Kornowski R, Hartmann F, Lansky AJ, Mehran R, Stone GW. Impact of Bivalirudin Therapy in High-Risk Patients With Acute Myocardial Infarction 1-Year Results From the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovascular Interventions 2010, 3: 796-802. PMID: 20723849, DOI: 10.1016/j.jcin.2010.05.009.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAntithrombinsChi-Square DistributionEptifibatideEuropeFemaleFibrinolytic AgentsHemorrhageHeparinHirudinsHumansImmunoglobulin Fab FragmentsIsraelKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPatient SelectionPeptide FragmentsPeptidesPlatelet Aggregation InhibitorsProspective StudiesRecombinant ProteinsRisk AssessmentRisk FactorsSecondary PreventionStentsTime FactorsTreatment OutcomeUnited StatesConceptsGlycoprotein IIb/IIIa inhibitorsHORIZONS-AMI trialHigh-risk patientsAcute myocardial infarctionRecurrent myocardial infarctionUnfractionated heparinMyocardial infarctionHigh riskPrimary percutaneous coronary interventionIIb/IIIa inhibitorsBaseline patient riskCADILLAC risk scoreIntermediate-risk groupPrimary percutaneous interventionPercutaneous coronary interventionHigh-risk groupLow-risk groupBivalirudin therapyMajor bleedingTrial patientsCoronary interventionIntermediate riskClinical variablesPercutaneous interventionPatient riskComparison of Catheterization Laboratory Initiated Abciximab and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes (an ACUITY Substudy)
Kirtane AJ, Parise H, Mehran R, Moses JW, Fahy M, Bertrand ME, Ohman EM, White HD, Feit F, Colombo A, McLaurin BT, Cox DA, Ware JH, Pocock SJ, Lansky AJ, Stone GW. Comparison of Catheterization Laboratory Initiated Abciximab and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes (an ACUITY Substudy). The American Journal Of Cardiology 2010, 106: 180-186. PMID: 20599000, DOI: 10.1016/j.amjcard.2010.03.015.Peer-Reviewed Original ResearchConceptsAcute coronary syndromePercutaneous coronary interventionCoronary syndromeCoronary interventionTreatment selectionHigh-risk acute coronary syndromesUrgent Intervention Triage Strategy (ACUITY) trialGlycoprotein IIb/IIIa inhibitorsBaseline cardiac risk factorsNet clinical adverse eventsIIb/IIIa inhibitorsPrevious revascularization proceduresUse of abciximabCardiac risk factorsStudy end pointClinical adverse eventsImproved clinical outcomesST-segment deviationAcute CatheterizationComposite ischemiaMajor bleedingIschemic complicationsAdverse eventsBiomarker elevationRevascularization procedures
2002
Gender differences in clinical outcome after coronary artery stenting with use of glycoprotein IIb/IIIa inhibitors
Iakovou I, Dangas G, Mehran R, Lansky AJ, Kobayashi Y, Adamian M, Polena S, Collins MB, Roubin GS, Stone GW, Leon MB, Moses JW. Gender differences in clinical outcome after coronary artery stenting with use of glycoprotein IIb/IIIa inhibitors. The American Journal Of Cardiology 2002, 89: 976-979. PMID: 11950440, DOI: 10.1016/s0002-9149(02)02251-8.Peer-Reviewed Original Research